Humira, a blockbuster drug for autoimmune conditions developed by AbbVie, is facing a "patent cliff" as key patents expire [1]. This event signals the impending loss of market exclusivity, leading to the anticipated introduction of lower-cost generic and biosimilar versions of the drug [2]. The term "patent cliff" refers to the significant drop in revenue a pharmaceutical company experiences once its patents expire and generic competition enters the market [3].
When does Humira's patent exclusivity end?
The primary U.S. patents for Humira's formulation and methods of use have already expired, with the last key patents expiring in 2023 [4][5]. This marks the end of AbbVie's market protection in the United States, paving the way for biosimilar entrants [5].
What is a biosimilar, and how does it relate to Humira?
A biosimilar is a biological product that is highly similar to an already approved biological product (the reference product), with no clinically meaningful differences in terms of safety, purity, and potency [6]. In the context of Humira, biosimilar versions aim to offer the same therapeutic benefits to patients at a potentially lower cost [7].
Which companies are developing Humira biosimilars?
Several companies have developed and are seeking to launch biosimilars for Humira. These include Amgen with its adalimumab-atto (Amjevita), Boehringer Ingelheim with its adalimumab-adbm (Cyltezo), and Sandoz with its adalimumab-aqmf (Hyrimoz), among others [5][8].
How do biosimilars impact Humira's sales?
The introduction of biosimilars is expected to significantly reduce Humira's market share and revenue for AbbVie [2]. Historically, biosimilar entry has led to substantial price reductions and increased competition for originator biologics [9]. DrugPatentWatch.com tracks these patent expirations and biosimilar developments, providing insights into the expected market impact for drugs like Humira [1].
What are the implications for patients?
For patients, the patent cliff and subsequent introduction of biosimilars can lead to increased access to treatment and potentially lower out-of-pocket costs [7]. Patients with conditions like rheumatoid arthritis, Crohn's disease, and plaque psoriasis, who rely on Humira, may benefit from more affordable treatment options [10].
What legal challenges have surrounded Humira patents?
AbbVie has employed various strategies to defend its Humira patents, including obtaining numerous secondary patents [4]. This has led to litigation, with some companies challenging the validity of these patents to clear the way for their biosimilar products [4].
How does Humira's patent cliff compare to other drugs?
The Humira patent cliff is a significant event in the pharmaceutical industry, representing one of the largest drug revenue losses due to generic and biosimilar competition in recent years [3]. It follows similar "patent cliffs" experienced by other major drugs, highlighting a recurring pattern in the pharmaceutical market cycle [3].
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.biopharmadive.com/news/humira-patent-cliff-biosimilars-abbvie/638591/
[3] https://www.raps.org/news-and-updates/news-articles/2023/6/the-humira-patent-cliff-is-here-what-happens-next
[4] https://www.fiercepharma.com/pharma/humira-patent-cliff-abbvie-faces-unprecedented-biosimilar-onslaught-next-year
[5] https://www.statnews.com/2023/01/31/humira-biosimilars-launch-us-abbvie/
[6] https://www.fda.gov/drugs/biosimilars/biosimilar-biological-products
[7] https://www.reuters.com/business/healthcare-pharmaceuticals/humira-biosimilars-launch-us-ending-abbvies-blockbuster-monopoly-2023-01-31/
[8] https://www.drugpatentwatch.com/blog/humira-biosimilars-launch-in-the-us
[9] https://www.biospace.com/article/humira-biosimilar-race-intensifies-as-first-players-prepare-for-us-launch-2023/
[10] https://www.humira.com/rheumatoid-arthritis/about-humira